Drug Patch Tests in Patients With Severe Cutaneous Adverse Reaction to Drugs (SCARs)

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

NA

Total Enrollment

30 participants

Study Classification

INTERVENTIONAL

Study Start Date

2016-08-04

Study Completion Date

2017-08-03

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The study is about drug patch tests in patients who have history of severe cutaneous drug reaction including Steven Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), Drug-induced eosinophilia and systemic symptoms (DRESS), AGEP (Acute generalized exanthematous pustulosis) and generalized bullous fixed drug eruptions. This study also investigate in Enzyme-linked immunosorbent spot assay (ELIspot) and lymphocyte transformation test. We also trying to prove the correlation among result of drug patch tests, ELIspot and LTT.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Severe Cutaneous Adverse Reactions in Thailand

NCT02574988

Steven-Johnson Syndrome Toxic Epidermal Necrolysis Drug Reaction With Eosinophilia and Systemic Symptoms +2 more

UNKNOWN

Role of Skin Tests for the Diagnosis of Immediate Hypersensitivity Reactions Due to Iodinated Contrast Media

NCT00819494

Hypersensitivity

COMPLETED NA

Clinical Evaluation of T.R.U.E. TEST® : Safety and Efficacy

NCT00640614

Contact Dermatitis

COMPLETED PHASE3

Clinical Evaluation of T.R.U.E. TEST Panel 3.2 in Children and Adolescents

NCT01518348

Contact Dermatitis

WITHDRAWN PHASE3

Study Will Assess Skin Irritation and Sensitization for HP-1050 Patch

NCT04624867

Cumulative Irritation and Sensitization

UNKNOWN PHASE1

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Drug Reaction

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

OTHER

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

patch test arm

Patch test by selected allergens and drawing blood for ELIspot and LTT

Group Type EXPERIMENTAL

patch test

Intervention Type OTHER

Patch test allergen from chemotechnique diagnostics, pure drug and drug as is combine with petrolatum or aqueous.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

patch test

Patch test allergen from chemotechnique diagnostics, pure drug and drug as is combine with petrolatum or aqueous.

Intervention Type OTHER

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Enzyme-linked immunosorbent spot assay (ELIspot) and lymphocyte transformation test (LTT)

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patients with history of Steven Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), drug-induced eosinophilia and systemic symptoms (DRESS), acute generalized exanthematous pustulosis (AGEP), generalized bullous fixed drug eruption in the past 24 months.
* Age more than 18 years old